EA035515B1 - Композиции на основе дейтерированного домперидона и способы терапии расстройств - Google Patents

Композиции на основе дейтерированного домперидона и способы терапии расстройств Download PDF

Info

Publication number
EA035515B1
EA035515B1 EA201891727A EA201891727A EA035515B1 EA 035515 B1 EA035515 B1 EA 035515B1 EA 201891727 A EA201891727 A EA 201891727A EA 201891727 A EA201891727 A EA 201891727A EA 035515 B1 EA035515 B1 EA 035515B1
Authority
EA
Eurasian Patent Office
Prior art keywords
domperidone
release
active agent
composition
acid
Prior art date
Application number
EA201891727A
Other languages
English (en)
Russian (ru)
Other versions
EA201891727A1 (ru
Inventor
Кэтрин Пирс
Джон Айзаксон
Пиюш Патель
Original Assignee
Синдом Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синдом Фарма, Инк. filed Critical Синдом Фарма, Инк.
Publication of EA201891727A1 publication Critical patent/EA201891727A1/ru
Publication of EA035515B1 publication Critical patent/EA035515B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201891727A 2016-02-04 2017-02-03 Композиции на основе дейтерированного домперидона и способы терапии расстройств EA035515B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291198P 2016-02-04 2016-02-04
PCT/US2017/016334 WO2017136617A1 (en) 2016-02-04 2017-02-03 Deuterated domperidone compositions and methods for therapy of disorders

Publications (2)

Publication Number Publication Date
EA201891727A1 EA201891727A1 (ru) 2018-12-28
EA035515B1 true EA035515B1 (ru) 2020-06-29

Family

ID=59501077

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891727A EA035515B1 (ru) 2016-02-04 2017-02-03 Композиции на основе дейтерированного домперидона и способы терапии расстройств
EA202090183A EA202090183A1 (ru) 2016-02-04 2018-06-28 Композиции, способы и получение дейтерированного домперидона

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090183A EA202090183A1 (ru) 2016-02-04 2018-06-28 Композиции, способы и получение дейтерированного домперидона

Country Status (11)

Country Link
US (2) US10266516B2 (enExample)
EP (2) EP3411031B1 (enExample)
JP (3) JP7296185B2 (enExample)
KR (2) KR102851614B1 (enExample)
CN (4) CN108697700B (enExample)
AU (2) AU2017213852B2 (enExample)
BR (2) BR112018016032B1 (enExample)
CA (2) CA3013123A1 (enExample)
DK (2) DK3411031T3 (enExample)
EA (2) EA035515B1 (enExample)
WO (2) WO2017136617A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR102851614B1 (ko) 2016-02-04 2025-08-29 신돔 파마, 인크. 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
KR20240125702A (ko) 2017-06-30 2024-08-19 신돔 파마, 인크. 중수소화 돔페리돈 조성물, 방법, 및 제조
KR20210022558A (ko) * 2018-06-21 2021-03-03 더마반트 사이언시즈 게엠베하 Dgat1 억제제의 국소 제형 및 이의 사용 방법
EP3681502B1 (en) * 2018-10-25 2021-03-17 CinDome Pharma, Inc. Formulations containing domperidone
CA3117682A1 (en) * 2018-10-25 2020-04-30 Cindome Pharma, Inc. Formulations containing deuterated domperidone
WO2022212246A1 (en) * 2021-03-29 2022-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Multi-enzyme nanoparticle-assisted stable isotope incorporation into small molecules by channeling
US20250268884A1 (en) * 2022-04-20 2025-08-28 Cindome Pharma, Inc. Deuterated Domperidone for Treating Gastroparesis
CN120813355A (zh) * 2023-03-23 2025-10-17 辛多美制药有限公司 用于治疗糖尿病性胃轻瘫的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US5652246A (en) * 1994-10-21 1997-07-29 Adir Et Compagnie Piperidine compounds
US5814339A (en) * 1994-02-28 1998-09-29 Janssen Pharmaceutica, N.V. Film coated tablet of paracetamol and domperidone
US20100255096A1 (en) * 2007-04-26 2010-10-07 Aronchick Craig A Compositions And Methods For Transmucosal Delivery Of Domperidone

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20140070440A1 (en) 2001-10-12 2014-03-13 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140163060A1 (en) 2001-10-12 2014-06-12 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20160206639A9 (en) 2001-10-12 2016-07-21 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
US20130220526A1 (en) 2001-10-12 2013-08-29 Monosol Rx, Llc Films and Drug Delivery Systems Made Therefrom
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
DK1545475T3 (da) 2002-10-01 2014-07-28 Banner Pharmacaps Inc Enterisk sammensætning til fremstillingen af blød kapselvæg
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
CN104083342A (zh) 2004-12-31 2014-10-08 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
ITMI20050477A1 (it) 2005-03-23 2006-09-24 Bouty S P A Cerotto transdermico
CN100386323C (zh) * 2006-02-27 2008-05-07 南京长澳医药科技有限公司 马来酸多潘立酮的合成方法
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
CN102895194B (zh) 2006-06-30 2015-09-09 伊休蒂卡有限公司 用于制备纳米粒形式的生物活性化合物的方法
JP5345620B2 (ja) 2007-08-15 2013-11-20 マクニール−ピーピーシー・インコーポレーテツド 即時放出及び徐放型イブプロフェンの投与法
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090076010A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009146310A1 (en) 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US20100113405A1 (en) * 2008-11-06 2010-05-06 Auspex Pharmaceuticals, Inc. Methylindazole modulators of 5-ht3 receptors
WO2010054158A2 (en) * 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
MY159208A (en) 2009-04-24 2016-12-30 Iceutica Pty Ltd A novel formulation of indomethacin
EP2421525B1 (en) 2009-04-24 2017-06-07 Iceutica Pty Ltd. Diclofenac formulation
CN102438592B (zh) 2009-04-24 2016-09-14 伊休蒂卡有限公司 甲氧萘普酸的剂型
WO2010121324A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of metaxalone
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
US20140017299A1 (en) 2011-08-18 2014-01-16 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same
CN107441069A (zh) 2012-02-28 2017-12-08 日绊株式会社 贴附剂
SMT202500302T1 (it) 2012-06-15 2025-09-12 Sun Pharmaceutical Industries Inc Derivati deuterati del ruxolitinib
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US20140019395A1 (en) 2012-07-12 2014-01-16 Craig Charles Bauer Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
US20140272220A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Reduction in stress cracking of films
US20140271787A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Continuous single layer film structure including discrete domains
CN105246598B (zh) 2013-03-15 2019-09-13 太阳药业环球公司 乙酸阿比特龙酯制剂
KR102851614B1 (ko) 2016-02-04 2025-08-29 신돔 파마, 인크. 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US5814339A (en) * 1994-02-28 1998-09-29 Janssen Pharmaceutica, N.V. Film coated tablet of paracetamol and domperidone
US5652246A (en) * 1994-10-21 1997-07-29 Adir Et Compagnie Piperidine compounds
US20100255096A1 (en) * 2007-04-26 2010-10-07 Aronchick Craig A Compositions And Methods For Transmucosal Delivery Of Domperidone

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Gaba et al. 'Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration', Drug Delivery, 27 March 2014 (27.03.2014), Vol. 22, page 691-700; p. 691, p. 695 *
Manivannan 'Oral disintegrating tablets: A future compaction', Drug Invention Today, 01 November 2009 (01.11.2009), Vol. 1, page 61-65; Abstract, p. 61, p. 63, p. 64 *
Mulatero 'Domperidone', 16 June 2014 (16.06.2014) (http://flipper.diff.org/appathwaysaccount/items/6886); p. 2, p. 7 *
Synfine Research, 'New Product Information', 26 November 2009 (26.11.2009), (http://synfine.com/pdfs/New_Product_Bulletin_November_26_2009 pdf); p. 1 *
The Economist 'Drugs that live long will prosper', 05 September 2015 (05.09.2015) (http://www.economist.com/news/science-and-technology/21663193-simple-change-some-pharmaceuticals-might-boost-their-efficacy-and-make-few); p. 2 *

Also Published As

Publication number Publication date
CN108697700B (zh) 2021-08-17
EP3411031A4 (en) 2019-08-07
CN113995755A (zh) 2022-02-01
CN111093653A (zh) 2020-05-01
AU2018290905B2 (en) 2022-10-06
AU2017213852A1 (en) 2018-07-05
JP7296185B2 (ja) 2023-06-22
JP2020534246A (ja) 2020-11-26
WO2019006078A1 (en) 2019-01-03
KR102851614B1 (ko) 2025-08-29
BR112019028185A8 (pt) 2020-08-11
BR112018016032A2 (pt) 2018-12-26
JP2019504068A (ja) 2019-02-14
EA201891727A1 (ru) 2018-12-28
US20190241543A1 (en) 2019-08-08
CN108697700A (zh) 2018-10-23
KR20180104662A (ko) 2018-09-21
EA202090183A1 (ru) 2020-04-15
JP2023052045A (ja) 2023-04-11
US10590110B2 (en) 2020-03-17
US10266516B2 (en) 2019-04-23
BR112018016032B1 (pt) 2024-03-05
CA3013123A1 (en) 2017-08-10
EP3411031B1 (en) 2024-07-24
AU2017213852B2 (en) 2021-04-08
CA3055777A1 (en) 2019-01-03
EP3644995B1 (en) 2025-05-07
WO2017136617A1 (en) 2017-08-10
EP3411031A1 (en) 2018-12-12
DK3411031T3 (da) 2024-10-21
JP7602324B2 (ja) 2024-12-18
KR102695402B1 (ko) 2024-08-16
US20170298046A1 (en) 2017-10-19
BR112019028185A2 (pt) 2020-07-07
CN116712432A (zh) 2023-09-08
WO2017136617A8 (en) 2017-10-05
CN111093653B (zh) 2023-06-23
DK3644995T3 (da) 2025-08-18
EP3644995A1 (en) 2020-05-06
KR20200044790A (ko) 2020-04-29
AU2018290905A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
US10590110B2 (en) Deuterated domperidone compositions, methods, and preparation
US11364226B2 (en) Deuterated domperidone compositions, methods, and preparation
US12478612B2 (en) Deuterated domperidone compositions, methods, and preparation
HK40064919A (en) Deuterated domperidone compositions and methods for therapy of disorders
ES3034905T3 (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
EA045546B1 (ru) Способ облегчения заболевания или состояния, связанного с моторикой желудочно-кишечного тракта, с использованием дейтерированного домперидона
HK40029064A (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
HK40029064B (en) Deuterated domperidone compounds for use in ameliorating gastroesophageal reflux disease
HK40001556A (en) Deuterated domperidone compositions and methods for therapy of disorders
HK40001556B (en) Deuterated domperidone compositions and methods for therapy of disorders
HK1259508A1 (en) Deuterated domperidone compositions and methods for therapy of disorders
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法
BR112019016091B1 (pt) Unidade de dosagem oral e uso de floroglucinol e trimetilfloroglucinol
EA046180B1 (ru) Фармацевтический состав флороглюцинола и триметилфлороглюцинола

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM